InSitu Biologics
View On Demand

Pain Management: A Physician's Perspective

About the Event

InSitu Biologics is a clinical stage pharmaceutical company with a disruptive drug delivery platform that increases safety and performance of treatments thanks to precision local delivery and proprietary controlled-release technology.

The first target of this technology is post-operative pain management due to the enormous size of the market and the huge benefit it will provide to society. Just one peripheral nerve block injection using InSitu’s technology provides 5 days of pain management with NO OPIOIDS! This extended relief platform offers new hope to the 100 million surgical patients whose only other option to manage pain is opioids. 

Join our fireside chat to get a physician’s perspective on pain management and the effect on patients when they are introduced to opioids featuring:

• Dr. Matthew Purcell: Staff anesthesiologist at SSM St Agnes Hospital and clinical advisor to InSitu

• Dr. Mark Ereth: Emeritus Professor at Mayo Clinic College of Medicine and Chief Medical Officer of InSitu

• Kevin Bassett: InSitu President and CEO

Doctors Purcell and Ereth will also talk about why they have chosen to invest in InSitu.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.